How we chose.
Start with the two systematic reviews, then the three human reports, then the laboratory papers those reviews are built on. Skip a paper when a later one from the same authors already says it.
The search was PubMed, for papers with BPC-157, “BPC 157,” or “pentadecapeptide BPC” in the title. From that set we took 30 papers that are actually about this peptide, not a passing mention. A paper made the page when it was a systematic review, a human report, an experiment from a laboratory other than Zagreb, or the original Zagreb experiment that later papers cite. A paper was set aside when it repeated a review we already kept.
The journal plate on each study is drawn for this page. It names the real journal and year. It is not the publisher’s cover, and the authors did not write, review or endorse this site.
What the reviews conclude.
The careful reviews agree on the shape of the evidence: a large pile of animal papers, mostly from one group, and almost nothing controlled in people.
01 · Systematic review · Humans
What the human evidence amounts to
J. T. Poolton, J. Minett and A. Kazmi, 2026
Three human reports, 30 people, and no comparison group.
1 Poolton, Minett and Kazmi gathered the published human studies. They found three, with 30 people in all. None compared BPC-157 with a placebo or with usual care. They rated the certainty of that evidence as very low, and they wrote that it should not be used in people outside a regulated clinical trial. This paper reviews other papers. It is not a new experiment.
Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PMID 42885452 doi:10.52628/92.3.15837
02 · Systematic review · Orthopaedic sports medicine
The animal literature, sorted
N. Vasireddi, H. Hahamyan, M. J. Salata and colleagues, 2025
Thirty-six studies, thirty-five of them preclinical.
2 Nikhil Vasireddi and colleagues reviewed BPC-157 research aimed at muscle, tendon, ligament and bone. Of 36 studies they judged relevant, 35 were preclinical (cells or animals) and one was clinical. A systematic review judges the papers that already exist. It does not show that the peptide works in people.
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. PMID 40756949 doi:10.1177/15563316251355551
03 · Critical review · Outside the original lab
An outside reading of the soft-tissue papers
Daniel Gwyer, Nicholas M. Wragg and Samantha L. Wilson, 2019
Most of the musculoskeletal experiments come from one laboratory.
3 Gwyer, Wragg and Wilson reviewed the tendon, ligament and muscle papers from outside the Zagreb group that produced most of them. They describe reported effects in animals, and they underline the limits: one dominant laboratory, and a peptide that is difficult to keep intact in the body. This is a critique of the literature, not a new experiment.
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID 30915550 doi:10.1007/s00441-019-03016-8
04 · Literature and patent review · Poland
The papers and the patents
Michalina Józwiak, Marta Bauer, Wojciech Kamysz and Patrycja Kleczkowska, 2025
A survey of published claims, written by people who did not do the original experiments.
4 Józwiak, Bauer, Kamysz and Kleczkowska read the scientific papers and the patents. They describe many reported effects in animal models and few reported side effects. A review can only be as strong as the studies underneath it, and those studies are mostly rat experiments from one group. The authors also discuss anti-doping rules. For the rule in force today, this site relies on the WADA Prohibited List, which lists BPC-157 under S0.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999 doi:10.3390/ph18020185
05 · Review · The Zagreb group on its own work
Their account of wound models
Sven Seiwerth, Predrag Sikirić and colleagues, 2021
A review by the laboratory that ran most of the experiments.
5 Seiwerth, Sikirić and their colleagues summarize their own animal work on skin wounds, burns and ulcers. Because the reviewers are also the experimenters, the paper is the group’s account of its research, not an independent check. Treat the reported effects as claims from that body of rat studies.
Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PMID 34267654 doi:10.3389/fphar.2021.627533
06 · Review · Cytoprotection
The idea behind the peptide
Predrag Sikirić, Ki-Baik Hahm and colleagues, 2020
Stomach protection, extended by the authors to other organs.
6 Sikirić, with Ki-Baik Hahm and the Zagreb group, argue that BPC-157 fits an older idea called cytoprotection: keeping a tissue lining intact after an insult, first in the stomach and then, they propose, elsewhere. The paper is their reading of decades of their own studies. Hahm is a coauthor from outside that core group. It is an argument, not a human trial.
Sikirić P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. Gut Liver. 2020;14(2):153–167. PMID 31158953 doi:10.5009/gnl18490
The three human reports.
These are the human studies Poolton and colleagues counted. Together they describe 30 people. None has a comparison group.
07 · Human report · No comparison group
A look back at knee charts
E. Lee and B. Padgett, 2021
Sixteen people’s charts. No untreated group.
7 Lee and Padgett looked back at the charts of 16 people who had been given BPC-157 for knee pain. There was no comparison group, so a change in a chart cannot be attributed to the peptide. Poolton and colleagues later rated this report poor quality. It is one of the three human papers in that review. This site does not describe a dose or a procedure.
Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PMID 34324435
08 · Human pilot · 12 people
A pilot in interstitial cystitis
E. Lee, C. Walker and B. Ayadi, 2024
Twelve people, and no comparison group.
8 Lee, Walker and Ayadi reported on 12 people with interstitial cystitis who received BPC-157. A pilot this small, without a comparison group, cannot show that a treatment works. The 2026 systematic review grouped it with the other human reports and judged the set poor quality. No dose is repeated here.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560
09 · Human pilot · Two people
Two people, watched for a short time
E. Lee and K. Burgess, 2025
A safety pilot, not a demonstration that the peptide is safe.
9 Lee and Burgess describe giving BPC-157 by vein to two people and watching for short-term problems. Two people, no comparison group, and a short window cannot establish safety. Reviewers have found no controlled safety data in people. This page does not repeat the amount they gave.
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143
Cells, vessels, and animal models.
Outside Zagreb, the clearest laboratory papers are two tendon-cell studies from Taiwan, a blood-vessel study, and a pharmacokinetics study in rats and dogs. The injury models underneath the reviews are the Zagreb rat papers.
10 · Laboratory · Rats and dogs
How quickly it leaves the blood
L. He, D. Feng, H. Guo, Y. Zhou and colleagues, 2022
Measured in animals. Gone from the bloodstream in under 30 minutes.
10 He and colleagues tracked BPC-157 through rats and beagle dogs: where it went, how it was broken down, and how fast it left. They reported an elimination half-life under 30 minutes. This is a pharmacokinetics study, not a human trial. The paper’s title calls the peptide a potential wound drug. That is the authors’ wording. BPC-157 is not an approved drug.
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717 doi:10.3389/fphar.2022.1026182
11 · Laboratory · Vessels
More blood vessels, in three lab models
M. J. Hsieh and colleagues, 2017
A chick-embryo membrane, human vessel cells, and rats.
11 Hsieh and colleagues reported more new blood vessels in a chick-embryo membrane, in human cells that line vessels, and in rats. They tied that to a receptor called VEGFR2. New vessels are part of ordinary repair. The same finding is why some reviewers worry, in theory, about tumor growth. This study did not test that worry, and it is not a clinical trial.
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. PMID 27847966 doi:10.1007/s00109-016-1488-y
12 · Cells in a dish · Rat tendon
A receptor signal goes up
C. H. Chang, W. C. Tsai, Y. H. Hsu and J. H. S. Pang, 2014
Tendon cells from rats, not a study in people.
12 Chang, Tsai, Hsu and Pang grew tendon cells from rats and reported that BPC-157 increased the cells’ growth-hormone receptor. The work was done in a dish, in one laboratory. Nothing in the paper was measured in a person.
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID 25415472 doi:10.3390/molecules191119066
13 · Cells in a dish · Rat tendon
Tendon cells spread and move
C. H. Chang, W. C. Tsai, M. S. Lin, Y. H. Hsu and J. H. S. Pang, 2011
A cell-adhesion pathway called FAK–paxillin.
13 The same Taiwan laboratory reported that rat tendon cells exposed to BPC-157 spread, survived and migrated more. They linked that behavior to FAK–paxillin, a pathway cells use to grip a surface and move. It is a dish experiment. It does not show repair of a tendon in a person.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID 21030672 doi:10.1152/japplphysiol.00945.2010
14 · Rat experiment · Muscle and tendon
A tendon pulled off its muscle
M. Japjec and colleagues, 2021
A junction the authors say does not close on its own in this model.
14 Japjec and colleagues separated the quadriceps tendon from the quadriceps muscle in rats. They reported better structure and strength when BPC-157 was given, judged by appearance, microscopy and mechanical testing. It is one laboratory’s rat model. This page does not repeat the dose.
Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021;9(11):1547. PMID 34829776 doi:10.3390/biomedicines9111547
15 · Rat experiment · Ligament
A cut knee ligament
T. Cerovecki and colleagues, including Seiwerth and Sikirić, 2010
Reported ligament repair in rats, with the peptide given alone.
15 Cerovecki, Bojanic, Seiwerth, Sikirić and colleagues cut a knee ligament in rats and reported better healing when BPC-157 was given on its own, without a carrier cream or scaffold. Rats only, and the same Zagreb laboratory as most of the injury papers. Not a human study.
Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161. PMID 20225319 doi:10.1002/jor.21107
16 · Rat experiment · Muscle
A crushed muscle
T. Novinscak and colleagues, 2008
Faster recovery, reported in one crush model.
16 Novinscak and colleagues crushed a muscle in rats and reported faster structural and functional recovery with BPC-157. The work is from the Zagreb group. A single animal model does not establish an effect in any other species, including people.
Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716–725. PMID 18668315 doi:10.1007/s00595-007-3706-2
17 · Rat experiment · Intestine
A rejoined piece of intestine
T. Vuksic and colleagues, 2007
The rat finding is the surgical join. The human-trial claim is not a published trial.
17 Vuksic and colleagues cut and rejoined the small intestine in rats and reported that the join held more often when BPC-157 was given. The title mentions human inflammatory-bowel-disease trials run under the names PL-10, PLD-116 and PL 14736. Those results are not published here as a full controlled study, so this page treats the rat operation as the finding and does not treat the trial claim as established.
Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768–777. PMID 17713731 doi:10.1007/s00595-006-3498-9
18 · Rat experiment · Tendon to bone
Tendon pulled off the heel bone
Andrija Krivic, Tomislav Anić, Sven Seiwerth, Dubravko Huljev and Predrag Sikirić, 2006
Reattachment, including when a corticosteroid was also given.
18 Krivic, Anić, Seiwerth, Huljev and Sikirić detached the Achilles tendon from the heel bone in rats. They reported that it reattached, including in animals also given a corticosteroid, which on its own tends to weaken that kind of repair. Rats only, one laboratory. No dose is repeated here.
Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID 16583442 doi:10.1002/jor.20096
19 · Rat experiment · Achilles tendon
The tendon paper later studies cite
M. Staresinic and colleagues, 2003
A cut Achilles tendon in rats, plus tendon cells in a dish.
19 Staresinic and colleagues cut the Achilles tendon in rats and also grew tendon cells in culture. They reported faster tendon repair and faster cell growth. Later tendon papers, including the Chang studies above, cite this one. It remains a rat study from the Zagreb group.
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PMID 14554208 doi:10.1016/S0736-0266(03)00110-4
20 · Early laboratory report
Where the healing claims started
Sven Seiwerth and Predrag Sikirić, 1997
A wide early survey, not a human trial.
20 Seiwerth and Sikirić, with their colleagues, reported effects of the 15-amino-acid peptide on several pieces of experimental healing. It is an early, broad laboratory paper. The later Zagreb injury studies grew out of this line of work. It is not evidence about people.
Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157’s effect on healing. J Physiol Paris. 1997;91(3–5):173–178. PMID 9403790 doi:10.1016/s0928-4257(97)89480-6
Ten we read and set aside.
These ten are real papers. Each one repeats a review we kept, or it is narrower than the experiment we featured in its place.
Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5–6):214–221. PMID 17186181 doi:10.1007/s10787-006-1531-7
Set aside. Same group’s essay on its trial program. The later Gut and Liver review covers the argument, and the human-trial results are not published as a paper we could assess.
Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60(Suppl 7):191–196. PMID 20388964
Set aside. A short angiogenesis note from Zagreb. Hsieh 2017 is the fuller vessel paper, and it comes from another laboratory.
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867 doi:10.2174/138161211796196954
Set aside. A gastrointestinal review from the same group, largely restated in the 2020 Gut and Liver paper we kept.
Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID 27138887 doi:10.2174/1570159x13666160502153022
Set aside. A theoretical review of the brain-gut idea. No new experiment, and the same laboratory.
Sikiric P, Seiwerth S, Rucman R, et al. Stress in gastrointestinal tract and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2017;23(27):4012–4028. PMID 28228068 doi:10.2174/1381612823666170220163219
Set aside. Another Zagreb review, this one framed around stress. It does not add a finding the 2020 paper does not already argue.
Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972–1989. PMID 29998800 doi:10.2174/1381612824666180712110447
Set aside. A growth-factor review that covers the same ground as the 2021 wound-healing review.
Wu H, Wei M, Li N, et al. Clopidogrel-induced gastric injury in rats is attenuated by stable gastric pentadecapeptide BPC 157. Drug Des Devel Ther. 2020;14:5599–5610. PMID 33376304 doi:10.2147/DDDT.S284163
Set aside. A real independent experiment, from Nanjing, in one rat model of stomach injury. Narrower than the papers we kept, so it is listed rather than featured.
Bilic Z, Gojkovic S, Kalogjera L, et al. Complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach. J Physiol Pharmacol. 2021;72(6). PMID 35485358 doi:10.26402/jpp.2021.6.11
Set aside. One very specific Zagreb rat model, a surgically perforated stomach. It does not change the picture drawn by the broader papers.
Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Biomedicines. 2022;10(12):3221. PMID 36551977 doi:10.3390/biomedicines10123221
Set aside. A muscle review that retells Japjec 2021 and earlier Zagreb experiments. We kept the experiment instead of the retelling.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMID 40789979 doi:10.1007/s12178-025-09990-7
Set aside. A narrative review that reaches the same caution as Vasireddi and Poolton. Those two used a systematic method, so they are the ones on the page.
Sources
Study authors are credited for their published research. None of them wrote, reviewed or endorsed this site. Citations 1–20 are the studies on this page. Citations 21–30 are the papers we read and set aside.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PMID 42885452 doi:10.52628/92.3.15837
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. PMID 40756949 doi:10.1177/15563316251355551
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID 30915550 doi:10.1007/s00441-019-03016-8
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999 doi:10.3390/ph18020185
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PMID 34267654 doi:10.3389/fphar.2021.627533
- Sikirić P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. Gut Liver. 2020;14(2):153–167. PMID 31158953 doi:10.5009/gnl18490
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PMID 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717 doi:10.3389/fphar.2022.1026182
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. PMID 27847966 doi:10.1007/s00109-016-1488-y
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID 25415472 doi:10.3390/molecules191119066
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID 21030672 doi:10.1152/japplphysiol.00945.2010
- Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021;9(11):1547. PMID 34829776 doi:10.3390/biomedicines9111547
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161. PMID 20225319 doi:10.1002/jor.21107
- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716–725. PMID 18668315 doi:10.1007/s00595-007-3706-2
- Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768–777. PMID 17713731 doi:10.1007/s00595-006-3498-9
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID 16583442 doi:10.1002/jor.20096
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PMID 14554208 doi:10.1016/S0736-0266(03)00110-4
- Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157’s effect on healing. J Physiol Paris. 1997;91(3–5):173–178. PMID 9403790 doi:10.1016/s0928-4257(97)89480-6
- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5–6):214–221. PMID 17186181 doi:10.1007/s10787-006-1531-7
- Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60(Suppl 7):191–196. PMID 20388964
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867 doi:10.2174/138161211796196954
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID 27138887 doi:10.2174/1570159x13666160502153022
- Sikiric P, Seiwerth S, Rucman R, et al. Stress in gastrointestinal tract and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2017;23(27):4012–4028. PMID 28228068 doi:10.2174/1381612823666170220163219
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972–1989. PMID 29998800 doi:10.2174/1381612824666180712110447
- Wu H, Wei M, Li N, et al. Clopidogrel-induced gastric injury in rats is attenuated by stable gastric pentadecapeptide BPC 157. Drug Des Devel Ther. 2020;14:5599–5610. PMID 33376304 doi:10.2147/DDDT.S284163
- Bilic Z, Gojkovic S, Kalogjera L, et al. Complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach. J Physiol Pharmacol. 2021;72(6). PMID 35485358 doi:10.26402/jpp.2021.6.11
- Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Biomedicines. 2022;10(12):3221. PMID 36551977 doi:10.3390/biomedicines10123221
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMID 40789979 doi:10.1007/s12178-025-09990-7